Related references
Note: Only part of the references are listed.Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Kenneth F. Grossmann et al.
CANCER DISCOVERY (2022)
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J. Luke et al.
LANCET (2022)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2021)
Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.
Kenneth F. Grossmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adjuvant nivolumab in high-risk stage IIb/IIc melanoma patients: Results from investigator initiated clinical trial.
Melissa Wilson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The Landmark Series: Randomized Trials Examining Surgical Margins for Cutaneous Melanoma
C. V. Angeles et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes)
Danielle M. Bello et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Cutaneous Melanoma Version 2.2019
Daniel G. Coit et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial
Deborah Utjes et al.
LANCET (2019)
Innovative approaches for cancer treatment: current perspectives and new challenges
Carlotta Pucci et al.
ECANCERMEDICALSCIENCE (2019)
MelMART Trial: It's Now or Never
Daniel Coit et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study
Marc D. Moncrieff et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michele Maio et al.
LANCET ONCOLOGY (2018)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
M. B. Faries et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Zeynep Eroglu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
Ulrike Leiter et al.
LANCET ONCOLOGY (2016)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
D. L. Morton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
Paolo A. Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The role of BRAF V600 mutation in melanoma
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial
Peter Gillgren et al.
LANCET (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Positive Nonsentinel Node Status Predicts Mortality in Patients with Cutaneous Melanoma
Charlotte Ariyan et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Sentinel-node biopsy or nodal observation in melanoma
Donald L. Morton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Excision margins in high-risk malignant melanoma
JM Thomas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick) -: Long-term results of a large European multicentric phase III study
D Khayat et al.
CANCER (2003)
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm)
CM Balch et al.
ANNALS OF SURGICAL ONCOLOGY (2000)
Share Paper
